Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGL

Classificação em ações #1969
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Preço da ação
$458.30
Última sincronização: 2026-10-21
Valor de mercado
$10.59B
Variação (1 dia)
-1.98%
Variação (1 ano)
10.18%
País
US
Negociar Madrigal Pharmaceuticals, Inc. (MDGL)

Categoria

Healthcare
Histórico de preços das ações de Madrigal Pharmaceuticals, Inc. (MDGL)
Preço de fecho mais alto: $472.49 em 2026-10-01

Preço de fecho mais baixo: $322.31 em 2007-02-01
Histórico de preços das ações da Madrigal Pharmaceuticals, Inc. de 2007 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) -11.50%
2025 85.56%
2024 36.19%
2023 46.99%
2022 95.20%
2021 -32.68%
2020 16.63%
2019 -6.63%
2018 32.71%
2017 414.16%
2016 26.67%
2015 -87.18%
2014 -42.14%
2013 -44.12%
2012 87.26%
2011 -19.61%
2010 10.34%
2009 1.71%
2008 -25.83%
2007 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$527.18 23.62%
US
$251.29 835.90%
US
$137.09 -4.30%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH